Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
clinical trials
deals
3
×
investing
3
×
life sciences
national blog main
san francisco blog main
3
×
boston
boston top stories
fda
national top stories
roche
san francisco top stories
akouos
amgen
astellas pharmaceuticals
avapritinib
blueprint medicines
california institute for biomedical research
cancer
cancer drugs
cobimetinib
cstone pharmaceuticals
decibel therapeutics
eli lilly
european medicines agency
fisogatinib
flatiron health
frequency therapeutics
genentech
harvard university
hearing loss
hepatocellular carcinoma
ipo
jeff albers
jeffrey karp
medullary thyroid cancer
multiple sclerosis
non-small cell lung cancer
What
drug
medicines
3
×
cancer
fda
ipo
affects
americans
approval
approved
blueprint
candidate
currently
date
despite
developing
family
frequency
hardest
hearing
hit
hottest
hunters
loss
marketing
meds
millions
muscle
pact
plans
proteins
ras
reels
regenerative
regulatory
research
ret
review
revolution
roche
targets
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
investing
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds